We claim:

1. A liquid pharmaceutical formulation for injection comprising:

(i) at least about 100 mg/ml of an antibody;

(ii) thiamine or a pharmaceutically acceptable salt thereof; and

(iii) a pharmaceutically acceptable solvent;

wherein the liquid pharmaceutical formulation, when in a volume suitable for injection, has an absolute viscosity of from about 1 cP to about 100 cP at 25°C as measured using a cone and plate viscometer or a microfluidic viscometer; and the absolute viscosity of the liquid pharmaceutical formulation is less than the absolute viscosity of a control formulation comprising the antibody and the pharmaceutically acceptable solvent, but without the thiamine or a pharmaceutically acceptable salt thereof;

wherein the absolute viscosity is an extrapolated zero-shear viscosity.

2. The liquid pharmaceutical formulation of claim 1, wherein the antibody is a monoclonal antibody.

3. The liquid pharmaceutical formulation of claim 1 or 2, wherein the antibody has a molecular weight of from about 120 kDa to about 250 kDa.

4. The liquid pharmaceutical formulation of any one of the previous claims, comprising from about 100 mg/ml to about 300 mg/ml of the antibody.

5. The liquid pharmaceutical formulation of any one of the previous claims, comprising from about 178 mg/ml to about 245 mg/ml of the antibody.

6. The liquid pharmaceutical formulation of any one of the previous claims, wherein the pharmaceutically acceptable solvent is aqueous.

7. The liquid pharmaceutical formulation of any one of the previous claims, wherein the thiamine or a pharmaceutically acceptable salt thereof is present at a concentration of from about 0.01 M to about 1.0 M.

8. The liquid pharmaceutical formulation of any one of the previous claims, wherein the thiamine or a pharmaceutically acceptable salt thereof is present at a concentration of from about 0.15 M to about 0.25 M.

9. The liquid pharmaceutical formulation of any one of the previous claims, further comprising one or more pharmaceutically acceptable excipients comprising a sugar, sugar alcohol, buffering agent, preservative, carrier, antioxidant, chelating agent, natural polymer, synthetic polymer, cryoprotectant, lyoprotectant, surfactant, bulking agent, stabilizing agent, or any combination thereof.

10. The liquid pharmaceutical formulation of claim 9, wherein the sugar alcohol is

sorbitol or mannitol.

11. The liquid pharmaceutical formulation of claim 9, wherein the one or more pharmaceutically acceptable excipients comprise a polysorbate, poloxamer 188, sodium lauryl sulfate, a polyol, a poly(ethylene glycol), glycerol, a propylene glycol, or a poly(vinyl alcohol).

12. The liquid pharmaceutical formulation of any one of the previous claims in a unit-dose vial, multidose vial, cartridge, or pre-filled syringe.

13. The liquid pharmaceutical formulation of any one of the previous claims, wherein the liquid pharmaceutical formulation is reconstituted from a lyophilized composition.

14. The liquid pharmaceutical formulation of any one of the previous claims, wherein the liquid pharmaceutical formulation is isotonic to human blood serum.

15. The liquid pharmaceutical formulation of any one of the previous claims, wherein the absolute viscosity is measured at a shear rate of at least about 0.5 s^{-1} when measured using a cone and plate viscometer, or a shear rate of at least about 1.0 s^{-1} when measured using a microfluidic viscometer.

16. The liquid pharmaceutical formulation of any one of the previous claims, characterized in that the liquid pharmaceutical formulation is to be administered to a subject, wherein the administration comprises subcutaneous or intramuscular injection.

17. The liquid pharmaceutical formulation of claim 16, wherein the injection is to be performed with a syringe.

18. The liquid pharmaceutical formulation of claim 17, wherein the syringe is a heated syringe, a self-mixing syringe, an auto-injector, a pre-filled syringe, or combinations thereof.

19. The liquid pharmaceutical formulation of claim 18, wherein the syringe is a heated syringe and the liquid pharmaceutical formulation is formulated to have an administration temperature between 25°C and 40°C.

20. The liquid pharmaceutical formulation of any one of claims 16-19, wherein the liquid pharmaceutical formulation is formulated to produce a primary irritation index of less than 3 when evaluated using a Draize scoring system.

21. The liquid pharmaceutical formulation of any one of claims 16-20, wherein the liquid pharmaceutical formulation is formulated to be administered with an injection force that is at least 10% less than an injection force for a control composition comprising the antibody and the pharmaceutically acceptable solvent, but without the thiamine or a pharmaceutically acceptable salt thereof, when administered in the same way.

22. The liquid pharmaceutical formulation of any one of claims 16-20, wherein the liquid pharmaceutical formulation is formulated to be administered with an injection force that is at least 20% less than an injection force for a control composition comprising the antibody and the pharmaceutically acceptable solvent, but without the thiamine or a pharmaceutically acceptable salt thereof, when administered in the same way.

23. The liquid pharmaceutical formulation of any one of claims 16-22, wherein the liquid pharmaceutical formulation is formulated for administration with a needle between 27 and 31 gauge in diameter and with an injection force less than 30 N with the 27 gauge needle.

24. A method of preparing the liquid pharmaceutical formulation of any one of claims 1-23, comprising the step of combining the antibody, the pharmaceutically acceptable solvent, and the thiamine or a pharmaceutically acceptable salt thereof.

25. A lyophilized composition comprising:

(i) an antibody;

(ii) thiamine or a pharmaceutically acceptable salt thereof; and

(iii) a pharmaceutically acceptable excipient.

26. The lyophilized composition of claim 25, wherein, once reconstituted, the antibody has a concentration of at least 100 mg/ml.